Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

COM701 in combination with nivolumab demonstrated encouraging 12% ORR in 3L+ MSS-CRC patients with liver metastases, compared to 0% ORR historically for other...

Related Keywords

Israel ,Boston ,Massachusetts ,United States ,Texas ,Tel Aviv ,Michael Overman ,Yvonne Naughton ,Society For Immunotherapy Of Cancer ,University Of Texas Md Anderson Cancer Center ,Compugen Ltd ,Stock Exchange ,Compugen ,Nasdaq ,Exchange Commission ,Astrazeneca ,Corporate Communications ,Securities Exchange ,Cancer Center ,South San Francisco ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,